You are here:
Myelodysplastic syndromes (MDS) low risk patients; transfusion-dependent and relapsed after or refractory to prior therapy (refractory to ESA).
No estimate possible yet
Registration application pending
Imetelstat
Hematology
New medicine (specialité)
AML / MDS
Geron
Enzyme inhibitor
Intravenous
Intravenous drip
Intermural (MSZ)
Fabrikant: Geron Corp. A first-in-class telomerase inhibitor.
Centralised (EMA)
No
September 2023
October 2024
Yes
Primary completion datum in augustus 2022. Inmiddels ingediend bij de FDA.
RBC transfusies
1 times every 4 weeks
7,5 mg/kg
NCT02598661
< 361
Market share is generally not included unless otherwise stated.
NKR2021(1); Expert opinie(2);
Aantal diagnoses myelodysplastisch syndroom in 2021 722 (1). Ongeveer de helft krijgt te maken met een relapse 361 (2).
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
Primary or secondary myelofibrosis.
SPS; ASH2018, paper no: 685
There is currently no futher information available.
Understanding of expected market entry of innovative medicines